What is a biosimilar for infliximab (Remicade)?

Prepare for the CPJE Law Test. Explore flashcards and multiple choice questions with detailed explanations. Ace your exam with comprehensive prep!

Biosimilars are highly similar versions of a biologic medicine with the same mechanism of action and clinical effect as the reference product. For infliximab (Remicade), a biosimilar would be another infliximab product, not a different biologic. Infliximab-dyyb (Inflectra) is the biosimilar of infliximab, matching Remicade in target and indications. The other options are biosimilars of different biologics (filgrastim, adalimumab, and etanercept), not infliximab. So the infliximab-dyyb product is the correct match.